{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:47:33Z","timestamp":1777312053257,"version":"3.51.4"},"reference-count":22,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Cardiac amyloidosis is a rare disorder caused by the myocardial deposition of abnormal fibrils. A 52-year-old man was referred to our center with clinical features of heart failure, after cardiac magnetic resonance imaging showed restrictive cardiomyopathy. Abdominal fat pad biopsy showed features of amyloidosis, and after hematological workup, he was diagnosed with Waldenstrom macroglobulinemia (WM). He was initiated on a rituximab-based chemotherapy regimen, and his cardiac function was assessed serially. Because of non-response, he was switched to a bortezomib-based regimen. Unfortunately, three days into this regimen, the patient died. WM is a rare plasma cell dyscrasia with a nonspecific presentation. It uncommonly presents with sequelae of amyloidosis\u2013the IgM subtype of amyloid-light chain (AL) amyloidosis. Diagnostic delays are common, contributing to an already poor prognosis. Amyloidosis in WM requires urgent treatment \u2013 clonal chemotherapy, and supportive cardiac care in heart involvement. Bortezomib-based regimens are commonly recommended, with diuretics as the mainstay for cardiac treatment. However, in most advanced cases, the prognosis is poor; thus, a high degree of suspicion is necessary for early diagnosis. This case illustrates the possible presentation of cardiac amyloidosis as a rare malignancy.<\/jats:p>","DOI":"10.5339\/qmj.2022.7","type":"journal-article","created":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T03:30:31Z","timestamp":1648956631000},"source":"Crossref","is-referenced-by-count":4,"title":["Rare Complication of a Rare Malignancy: Case Report of Cardiac Amyloidosis Secondary to Waldenstrom Macroglobulinemia"],"prefix":"10.5339","volume":"2022","author":[{"given":"Aaron","family":"Charles Lobo","sequence":"first","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Bhat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, St. John's Medical College, Bangalore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seetharam","family":"Anandram","sequence":"additional","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthala","family":"Devi A.M","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Immunohematology, St. John's Medical College, Bangalore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjukta S.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge-vivin","family":"Vinister","sequence":"additional","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Lobo","sequence":"additional","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecil","family":"Reuben Ross","sequence":"additional","affiliation":[{"name":"Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India E-mail: loboaaron@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"issue":"1:","key":"CIT0001","series-title":"JACC: Cardiooncology","first-page":"117\u201330","article-title":"AL Amyloidosis for the cardiologist and oncologist","year":"2019;"},{"issue":"121:","key":"CIT0002","series-title":"Circ Res","first-page":"819\u201337","article-title":"Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","year":"2017;"},{"issue":"32:","key":"CIT0003","series-title":"Adv Ther","first-page":"920\u20138","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","year":"2015;"},{"issue":"165:","key":"CIT0004","series-title":"Br J Haematol","first-page":"316\u201333","article-title":"Guidelines on the diagnosis and management of Waldenstr\u00f6m macroglobulinaemia","year":"2014;"},{"issue":"2004:","key":"CIT0005","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"257\u201382","article-title":"Amyloidosis and Waldenstr\u00f6m's macroglobulinemia","year":"2004;"},{"issue":"33:","key":"CIT0006","series-title":"Leukemia","first-page":"790\u20134","article-title":"Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia","year":"2019;"},{"issue":"66:","key":"CIT0007","series-title":"Indian Heart J","first-page":"473\u20136","article-title":"Cardiac amyloidosis: a report of two cases","year":"2014;"},{"issue":"99:","key":"CIT0008","series-title":"Haematologica","first-page":"1239\u201347","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","year":"2014;"},{"issue":"134:","key":"CIT0009","series-title":"Blood","first-page":"2022\u201335","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","year":"2019;"},{"issue":"120:","key":"CIT0010","series-title":"Blood (ASH Annual Meeting Abstracts)","first-page":"438","article-title":"Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study","year":"2012;"},{"issue":"34:","key":"CIT0011","series-title":"Leukemia","first-page":"1373\u201382","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","year":"2020;"},{"issue":"1:","key":"CIT0001","series-title":"JACC: Cardiooncology","first-page":"117\u201330","article-title":"AL Amyloidosis for the cardiologist and oncologist","year":"2019;"},{"issue":"121:","key":"CIT0002","series-title":"Circ Res","first-page":"819\u201337","article-title":"Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","year":"2017;"},{"issue":"32:","key":"CIT0003","series-title":"Adv Ther","first-page":"920\u20138","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","year":"2015;"},{"issue":"165:","key":"CIT0004","series-title":"Br J Haematol","first-page":"316\u201333","article-title":"Guidelines on the diagnosis and management of Waldenstr\u00f6m macroglobulinaemia","year":"2014;"},{"issue":"2004:","key":"CIT0005","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"257\u201382","article-title":"Amyloidosis and Waldenstr\u00f6m's macroglobulinemia","year":"2004;"},{"issue":"33:","key":"CIT0006","series-title":"Leukemia","first-page":"790\u20134","article-title":"Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia","year":"2019;"},{"issue":"66:","key":"CIT0007","series-title":"Indian Heart J","first-page":"473\u20136","article-title":"Cardiac amyloidosis: a report of two cases","year":"2014;"},{"issue":"99:","key":"CIT0008","series-title":"Haematologica","first-page":"1239\u201347","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","year":"2014;"},{"issue":"134:","key":"CIT0009","series-title":"Blood","first-page":"2022\u201335","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","year":"2019;"},{"issue":"120:","key":"CIT0010","series-title":"Blood (ASH Annual Meeting Abstracts)","first-page":"438","article-title":"Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study","year":"2012;"},{"issue":"34:","key":"CIT0011","series-title":"Leukemia","first-page":"1373\u201382","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","year":"2020;"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/1\/article-7.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/1\/article-7.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/1\/article-7.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:11:11Z","timestamp":1777309871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/1\/article-7.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":22,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2022.7","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}